An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Public ClinicalTrials.gov record NCT03662659. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Study identification
- NCT ID
- NCT03662659
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 274 participants
Conditions and interventions
Interventions
- BMS-986213 Biological
- Nivolumab Biological
- XELOX Drug
- FOLFOX Drug
- SOX Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2018
- Primary completion
- Aug 26, 2020
- Completion
- Jan 17, 2024
- Last update posted
- Feb 4, 2025
2018 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 7
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0049 | Clovis | California | 93611 | — |
| Local Institution - 0064 | Duarte | California | 91010-3012 | — |
| Scripps Clinic | La Jolla | California | 92037 | — |
| Local Institution - 0040 | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| Local Institution - 0041 | Orange | California | 92868 | — |
| Local Institution - 0077 | Santa Monica | California | 90404 | — |
| Local Institution - 0056 | Aurora | Colorado | 80045 | — |
| Local Institution - 0062 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0050 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0054 | Dallas | Texas | 75216 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Local Institution - 0052 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03662659, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 4, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03662659 live on ClinicalTrials.gov.